



**HAL**  
open science

## Unbalanced reporting of benefits and harms in abstracts on rofecoxib

Anders W. Jørgensen, Karsten Juhl Jørgensen, Peter C. Gøtzsche

► **To cite this version:**

Anders W. Jørgensen, Karsten Juhl Jørgensen, Peter C. Gøtzsche. Unbalanced reporting of benefits and harms in abstracts on rofecoxib. *European Journal of Clinical Pharmacology*, 2010, 66 (4), pp.341-347. 10.1007/s00228-010-0791-8 . hal-00566726

**HAL Id: hal-00566726**

**<https://hal.science/hal-00566726>**

Submitted on 17 Feb 2011

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# Unbalanced reporting of benefits and harms in abstracts on rofecoxib

Anders W. Jørgensen · Karsten Juhl Jørgensen · Peter C. Gøtzsche

Received: 19 August 2009 / Accepted: 19 January 2010 / Published online: 17 February 2010  
© Springer-Verlag 2010

## Abstract

**Purpose** It was predicted from the mechanism of action that, compared to older non-steroidal anti-inflammatory drugs, rofecoxib (Vioxx) would reduce gastrointestinal bleeding, but also that it would increase the occurrence of cardiovascular thrombosis. From the patient's point of view, both effects are important and should be investigated and reported similarly. We studied how they have been reported over time.

**Methods** We searched PubMed for abstracts on rofecoxib that commented on gastrointestinal bleeding or cardiovascular thrombosis or both. Two researchers, blinded to date of publication and authors, assessed the abstracts independently. We judged the authors' view on rofecoxib and comments on gastrointestinal bleeding and thrombosis as being favourable, neutral or unfavourable towards rofecoxib.

**Results** We included 393 abstracts commenting on gastrointestinal bleeding (72%) and cardiovascular thrombosis (54%) or both. Before October 2000, all abstracts ( $n=27$ ) mentioned only gastrointestinal bleeding and 89% were positive towards rofecoxib. The year before the withdrawal of rofecoxib (October 2003 to September 2004) ( $n=46$ ), 59% of abstracts commented on gastrointestinal bleeding only, 17% on thrombosis only, 24% on both and 67% were still positive. From October 2006 to September 2007 ( $n=54$ ), 13% mentioned gastrointestinal

bleeding, 54% thrombosis, 33% mentioned both and only 11% were positive.

**Conclusions** The reporting of benefits and harms was not balanced and changed markedly over time. Knowledge of increased risk of thrombosis existed early on, but the harms came into focus too late, when the drug was already withdrawn, and when tens of thousands of patients had been harmed unnecessarily.

**Keywords** Rofecoxib · Cyclooxygenase-2 inhibitors · Abstracts · Bias · Thrombosis · Gastrointestinal bleeding

## Introduction

Rofecoxib was marketed in 1999 as first-line treatment of osteoarthritis with the claim that it reduced pain as effectively as conventional non-steroidal anti-inflammatory drugs (NSAIDs), but with less gastrointestinal bleeding. However, the drug also caused serious thrombotic cardiovascular events [1, 2]. On 30 September 2004, Merck, the manufacturer, withdrew it from the market. Rofecoxib has been estimated to have caused the death of tens of thousands of patients because of thromboses [3].

The part of a paper that is most often read is the abstract and sometimes clinical decisions are based solely on abstracts [4, 5]. The recently published CONSORT guideline for abstracts states that any important adverse (or unexpected) effects of an intervention should be described in the abstract [5]. We quantified how often benefits and harms in terms of gastrointestinal bleeding and cardiovascular thrombosis, respectively, were reported in abstracts on rofecoxib, how often the drug was described favourably, and how this pattern changed over time.

A. W. Jørgensen (✉) · K. J. Jørgensen · P. C. Gøtzsche  
The Nordic Cochrane Centre,  
Department 3343, Rigshospitalet, Blegdamsvej 9,  
2100 Copenhagen, Denmark  
e-mail: awj@cochrane.dk

## Methods

### Search strategy and data extraction

One author searched PubMed (24 September 2007) using the search terms “Vioxx OR rofecoxib”. All records with an abstract were assessed for inclusion by two observers independently. At the same time, they extracted the data using a pilot-tested data sheet. Any disagreements were settled by discussion. The observers were blinded to any information about authors and institutions and to the date of publication, and assessed only the title and the text of the abstract. The blinding was obtained by exporting the relevant parts of the PubMed records into Microsoft Excel.

### Inclusion and exclusion criteria

We included abstracts that commented on the effect of rofecoxib on gastrointestinal bleeding or cardiovascular thrombosis or both, and contained a comment reflecting the authors' view on rofecoxib. We accepted abstracts that implicitly referred to these harms by using phrases such as “gastrointestinal adverse effect” and “cardiovascular risk”. We also included abstracts that commented on the effect of cyclooxygenase 2 (COX-2) inhibitors and other NSAIDs in general when these included rofecoxib, albeit indirectly, e.g. “celecoxib had no tangible advantage in terms of serious gastrointestinal complications ... overall mortality was higher with celecoxib than in the placebo group. The difference was similar to that observed in placebo-controlled trials of rofecoxib in Alzheimer's disease.”

We excluded abstracts that only commented on harms that did not involve gastrointestinal bleeding or cardiovascular thrombosis, such as nausea or hypertension. We also excluded abstracts that did not have a comment reflecting the authors view on rofecoxib, e.g. “The manufacturer claims that in clinical studies rofecoxib inhibits COX-2 but not COX-1, has the power of high-dose NSAIDs—diclofenac and ibuprofen—and superior GI [gastrointestinal] safety profile compared to conventional NSAIDs.” Abstracts of in vitro studies, animal studies, medical devices and pharmacokinetics were also excluded.

### Evaluation of the authors' view on rofecoxib

We categorised the authors' view on rofecoxib as either favourable, neutral or unfavourable. If an active comparator was not used as a reference, we accepted placebo or statements that did not involve a comparator. The judgement was preferentially made using the conclusion of the abstract. If this was not possible, we used statements in the results section or elsewhere, e.g. “Because of its more favorable gastrointestinal toxicity profile compared with

non-selective NSAIDs, rofecoxib is safer in patients ...”. We also judged the individual comments on gastrointestinal bleeding and cardiovascular thrombosis in the same way.

### Analysis

We used graphs and descriptive statistics to assess how the reporting in abstracts changed over time. Because rofecoxib was withdrawn on 30 September 2004, our 1-year intervals are from October to September, e.g. year 2000 was defined as October 1999 to September 2000, both months included. For abstracts that only contained information about the year of publication, we used the date the citation was added to the PubMed database [EDAT].

## Results


Our PubMed search identified 2,047 records and we included 393 abstracts. Most records were excluded because there was no abstract in PubMed or because the abstract did not contain a comment on gastrointestinal bleeding or cardiovascular thrombosis (Fig. 1). Twenty-nine of the excluded abstracts mentioned hypertension, but did not comment on cardiovascular thrombosis.

### Reporting of harms over time

During the whole observation period, 181 of the included abstracts (46%) commented on gastrointestinal bleeding only, 110 (28%) on cardiovascular thrombosis only and 102 (26%) commented on both. Of the 283 (181+102) abstracts commenting on gastrointestinal bleeding, 141 (50%) used the explicit terms “ulcer”, “gastrointestinal bleeding” or “perforation”, or “serious gastrointestinal adverse effect”. The remaining 142 abstracts (50%) used the less explicit terms “gastrointestinal risk”, “gastrointestinal safety”, or “gastrointestinal adverse effect”. Of the 212 (110+102) abstracts commenting on cardiovascular thrombosis, 137 (65%) used the explicit terms “thrombosis”, “thromboembolic” or “thrombotic effect”, “myocardial infarction” or “stroke”. The remaining 75 abstracts (35%) used the less explicit terms “cardiovascular risk”, “cardiovascular safety” or “cardiovascular adverse effect”.

Until and including September 2000, no abstracts commented on cardiovascular thrombosis (the first was published in November 2000), i.e. 100% ( $n=27$ ) of the abstracts commented only on gastrointestinal bleeding (Fig. 2). The percentage of abstracts that only commented on gastrointestinal bleeding decreased to 59% in 2004 ( $n=46$ ), before rofecoxib was withdrawn, and to 13% in 2007 ( $n=54$ ). The percentage of abstracts that commented only on cardiovascular thrombosis increased from 0 to 17% in

**Fig. 1** Search for relevant abstracts



2004 and to 54% in 2007. The percentage commenting on both gastrointestinal bleeding and cardiovascular thrombosis increased from 0 to 24% in 2004, and to 33% in 2007. The greatest change in reporting was seen immediately after the withdrawal of rofecoxib in 2004 (Fig. 2).

**Authors' general view on rofecoxib over time**


Until and including September 2000 ( $n=27$ ), the proportion of abstracts favouring rofecoxib was 89%. In 2004 ( $n=46$ ), it was 67%. The greatest change was seen after the withdrawal of rofecoxib and in 2007 ( $n=54$ ) where only

11% of the abstracts were positive (Fig. 3). We investigated the robustness of this result by including only those abstracts where our judgement was based on the conclusion section of the abstracts. This graph had a similar slope (dotted line in Fig. 3).


**Authors' views on harms before and after the withdrawal of rofecoxib**

Two hundred and eleven abstracts (54%) were published before the withdrawal of rofecoxib in 2004 and 182 (46%) were published after.

**Fig. 2** Abstracts published per year. Total number of abstracts published per year and percentage commenting on gastrointestinal bleeding, cardiovascular thrombosis or both. The three proportions add up to 100%



**Fig. 3** Abstracts favouring rofecoxib. Percentage of abstracts favouring rofecoxib among those commenting on gastrointestinal bleeding, cardiovascular thrombosis or both



Before the withdrawal, 193 (91%) abstracts commented on gastrointestinal bleeding, and 168 (87%) of them were favourable towards rofecoxib, 19 (10%) were neutral and 6 (3%) unfavourable. Fifty-six (27%) abstracts commented on cardiovascular thrombosis, and 5 (9%) of those were favourable towards rofecoxib, 31 (55%) neutral and 20 (36%) unfavourable.

After the withdrawal, the effect on gastrointestinal bleeding was mentioned in 89 (49%) abstracts, and 67 (75%) of those were favourable towards rofecoxib, 14 (16%) neutral and 8 (9%) unfavourable. The thrombotic effect was mentioned in 156 (86%) abstracts and, none of them were favourable towards rofecoxib, 26 (17%) neutral and 130 (83%) unfavourable.

## Discussion

We found that most abstracts on rofecoxib reported only on the beneficial effect regarding less gastrointestinal bleeding, and that they were generally in favour of rofecoxib, from the introduction of the drug in 1999 to its withdrawal in 2004. After the withdrawal, most abstracts reported on the harmful effects, cardiovascular thrombosis, and few were in favour of rofecoxib.

Such findings might be expected for drugs with important but rare harms that are unknown when the drugs

are introduced on the market and only discovered later. However, this is not the only explanation for our findings. It has been documented that the company suppressed cardiovascular harms in the scientific literature [6] and intimidated researchers and speakers who were critical of rofecoxib [6–8].

Before its introduction, it was predicted from the mechanism of action that the drug should reduce the incidence of gastrointestinal bleeding [9] but also increase the incidence of thrombosis, compared with non-selective NSAIDs [10–12]. Two trials conducted by Merck, 090 [3, 13, 14] and VIGOR [15], both showed that rofecoxib increased the risk of cardiovascular events significantly. However, the first trial, which ended in 1999, was not published in a scientific journal until 2006 [14]. The second trial was published in the *New England Journal of Medicine*, but the increased risk of myocardial infarction was interpreted as a beneficial aspirin-like prophylactic effect of the control NSAID [15]. This interpretation was speculative and was later refuted. Furthermore, three cases of myocardial infarction in the rofecoxib arm had been omitted from the paper [16].

In 2001, it was documented in a systematic review that COX-2 inhibitors increased the risk of cardiovascular events [17], and a cumulative meta-analysis of trials from 2004 showed that a clear relationship between rofecoxib and increased risk of myocardial infarction existed already

**Neurological disorders**

Hemicrania continua  
Schizophrenia  
Sclerosis  
Alzheimer's dementia  
Migraine  
Premenstrual migraine

**Surgery**

Prevention of urethral strictures after TURP  
Pre-medication for tonsilectomy  
Pre-medication for uterine curettage  
Hernia operations  
Post CABG  
Pre-medication for ear-nose-throat surgery in general  
Minor dental surgery (e.g. removal of molars)  
Minor orthopaedic surgery

**Cancer**

Treatment for glioblastoma multiforme  
Protection against colorectal neoplasia in familial polyposis  
Treatment of malignant melanoma and sarcomas  
Treatment of prostate cancer  
Treatment of bone cancer  
Treatment of breast cancer  
Treatment of lung cancer

**Other**

Reduction of atherosclerosis among ACS-patients post-infarction  
Congenial nephrogenous diabetes insipidus  
Menstrual pain  
Endometriosis  
Non-bacterial prostatitis  
Haemophilic arthropathy  
Premenstrual acne  
Prevention of ectopic ossification in arthroplasty

**Fig. 4** Conditions for which the effect of rofecoxib was mentioned

by the end of 2000 [18]. Two other meta-analyses did not find evidence of an increase in cardiovascular risk with rofecoxib, but they were conducted by employees of Merck [19, 20].

Over the studied time period, there has been an increased focus on harms [21–23] and the quality of reporting trial results in abstracts [5], which may have had an impact on our results. However, our sample of abstracts did not exclusively consist of trial abstracts, and the increased attention to harms does not explain the dramatic change in focus from beneficial to harmful effect when rofecoxib was withdrawn.

The safety data from trials on rofecoxib were far too positive compared to a real-world setting. None of the trials in the application for marketing approval were designed to evaluate the cardiovascular risk [6]. In fact, they included patients that had an unusually *low* cardiovascular risk. Medicare patients in Tennessee, who were treated with rofecoxib in clinical practice, had a baseline risk of getting a myocardial infarction that was eight times higher than that for the patients in the trials [18]. Patients at high risk of developing peptic ulcers were also often left out of trials on

rofecoxib. In 2002, an analysis of cardiovascular adverse events was added to the protocols of three studies [23] including the one [2] that led to the withdrawal of rofecoxib [1]. This was considered breaking news and is likely to have initiated the change in focus from beneficial effects to harms.

Publishing and disseminating scientific papers on medical interventions is an important marketing strategy for the pharmaceutical industry [24], and Merck's active role in the writing of journal articles is likely to have influenced how rofecoxib was portrayed and perceived by the clinicians. It is difficult to explore Merck's role in more detail in relation to our results. Merck's information control could have been clarified by looking at reporting in relation to type of financial support. We did not attempt to do this, as ghost authorship and other forms of support from drug companies are often not revealed in scientific papers [25], and Merck used guest and ghost authors for many of the papers on rofecoxib [26]. Merck also conducted a seeding trial [27], the ADVANTAGE trial, published in *Annals of Internal Medicine* [28], and sponsored the *Australasian Journal of Bone and Joint Medicine*, which looked like a peer-reviewed medical journal but was only a marketing tool. Most of the articles in the journal presented data favourable to Merck products, including rofecoxib, without disclosing sponsorship [29].

A strategy to increase drug sales that has been used by Merck [30] and many other drug companies is to stimulate off-label use [24, 31]. This may also be the case for rofecoxib [32] and could explain why many abstracts mentioned or evaluated the effect of rofecoxib in relation to other conditions than arthritis (Fig. 4). After having assessed one-third of the abstracts ( $n=1,370$ ), one observer decided to register the conditions (apart from arthritis) that rofecoxib was proposed for. These were mainly neurological disorders, cancer and pain related to minor surgery. The U.S. Food and Drug Administration approved rofecoxib for osteoarthritis, acute pain, primary dysmenorrhea and rheumatoid arthritis.

We searched for abstracts in PubMed only, as PubMed is the most widely used database for medical research. It is likely that more abstracts would have been included if we had searched additional databases, but we would not expect it to have led to any important changes in our results.

It has been suggested that increases in blood pressure related to rofecoxib are a mechanism for the increase in the risk of cardiovascular events [33]. We excluded 26 abstracts for the reason that they only commented on hypertension, but they would not have changed the results much as they were scattered over the years 2001 to 2007.

We believe that if the reporting of benefits and harms in abstracts is unbalanced, doctors will get a false perception of the drug's value. In particular, readers need information

on deaths, and on harms that can be lethal, such as thromboses caused by COX-2 inhibitors. In the drug literature, there is plenty of evidence of flawed research [34–43], ghost-written articles [24, 25, 44–47], intimidation of researchers [44, 45, 48–56] and misleading and false statements in research papers and marketing [24, 44–47, 57–65].

We suggest that studies like ours should be done on other drugs than rofecoxib, preferably with newly marketed drugs associated with high expectations.

## Conclusions

The basic principle of balanced reporting of benefits and harms seems to have been seriously distorted in abstracts on rofecoxib, although the harms were equally predictable as the benefits from the mechanism of action of the drug. Before the withdrawal of rofecoxib, abstracts mostly reported on gastrointestinal bleeding and were in favour of rofecoxib. The harms came in focus too late, when the drug had already been withdrawn, and when tens of thousands of patients had been harmed unnecessarily [3, 66, 67].

**Funding** None.

## References

- Merck News Release (2004) Merck announces voluntary worldwide withdrawal of VIOXX. [http://www.merck.com/newsroom/vioxx/pdf/vioxx\\_press\\_release\\_final.pdf](http://www.merck.com/newsroom/vioxx/pdf/vioxx_press_release_final.pdf). Accessed 23 June 2009
- Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanan A, Konstam MA, Baron JA, Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. *N Engl J Med* 352:1092–1102
- U.S. Senate Finance Committee (2004) Testimony of David J. Graham, MD, MPH, November 18 <http://finance.senate.gov/hearings/testimony/2004test/111804dgtest.pdf>. Accessed 23 June 2009
- Barry HC, Ebell MH, Shaughnessy AF, Slawson DC, Nietzsche F (2001) Family physicians' use of medical abstracts to guide decision making: style or substance? *J Am Board Fam Pract* 14:437–442
- Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF (2008) CONSORT for reporting randomised trials in journal and conference abstracts. *Lancet* 371:281–283
- Krumholz HM, Ross JS, Presler AH, Egilman DS (2007) What have we learned from Vioxx? *BMJ* 334:120–123
- Fries JF (2001) Letter to Raymond Gilmartin re: physician intimidation. 9 Jan. Merck. Bates No MRK-ABH0002204 to MRK-ABH0002207. [http://www.vioxxdocuments.com/Documents/Krumholz\\_Vioxx/Fries2001.pdf](http://www.vioxxdocuments.com/Documents/Krumholz_Vioxx/Fries2001.pdf). Accessed 23 June 2009
- Rout M (2009) Vioxx maker Merck and Co drew up doctor hit list. *The Australian*. <http://www.theaustralian.news.com.au/business/story/0,25272600-5018983,00.html>. Accessed 23 June 2009
- Knijff-Dutmer EAJ, Martens A, vander Laar MAFJ (1999) Effects of nabumetone compared with naproxen on platelet aggregation in patients with rheumatoid arthritis. *Ann Rheum Dis* 58:257–259
- Schonbeck U, Sukhova GK, Graber P, Coulter S, Libby P (1999) Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. *Am J Pathol* 155:1281–1291
- Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L, Lasseter KC, Quan H, Gertz BJ, FitzGerald GA (1999) Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. *J Pharmacol Exp Ther* 289:735–741
- McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA (1999) Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. *Proc Natl Acad Sci USA* 96:272–277
- US Food and Drug Administration (2001) Memorandum. [http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2\\_06\\_cardio.pdf](http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_06_cardio.pdf). Accessed 23 June 2009
- Weaver AL, Messner RP, Storms WW, Polis AB, Najarian DK, Petruschke RA, Geba GP, Tershakovec AM (2006) Treatment of patients with osteoarthritis with rofecoxib compared with nabumetone. *J Clin Rheumatol* 12:17–25
- Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ, VIGOR Study Group (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. *N Engl J Med* 343:1520–1528
- Curfman GD, Morrissey S, Drazen JM (2005) Expression of concern: Bombardier et al, "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis" *N Engl J Med* 2000;343:1520–1528. *N Engl J Med* 353:2813–14
- Mukherjee D, Nissen SE, Topol EJ (2001) Risk of cardiovascular events associated with selective COX-2 inhibitors. *JAMA* 286:954–959
- Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M (2004) Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. *Lancet* 364:2021–2029
- Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, Gertz BJ (2001) Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. *Circulation* 104:2280–2288
- Reicin AS, Shapiro D, Sperling RS, Barr E, Yu Q (2002) Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). *Am J Cardiol* 89:204–209
- Ioannidis JPA, Evans SJW, Gøtzsche PC, O'Neill RT, Altman DG, Schulz K, Moher D, for the CONSORT Group (2004) Better reporting of harms in randomized trials: an extension of the CONSORT statement. *Ann Intern Med* 141:781–788
- Bernal-Delgado E, Fisher ES (2008) Abstracts in high profile journals often fail to report harm. *BMC Med Res Methodol* 8:14
- Kim PS, Reicin AS (2004) Rofecoxib, Merck, and the FDA. *N Engl J Med* 351:2875–2878
- Steinman MA, Bero LA, Chren MM, Landefeld CS (2006) Narrative review: the promotion of gabapentin: an analysis of internal industry documents. *Ann Intern Med* 145:284–293
- Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW (2007) Ghost authorship in industry-initiated randomised trials. *PLoS Med* 4:e19
- Ross JS, Hill KP, Egilman DS, Krumholz HM (2008) Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. *JAMA* 299:1800–1812
- Hill KP, Ross JS, Egilman DS, Krumholz HM (2008) The ADVANTAGE seeding trial: a review of internal documents. *Ann Intern Med* 149:251–258

28. Lisse JR, Perlman M, Johansson G, Shoemaker JR, Schechtman J, Skalky CS, Dixon ME, Polis AB, Mollen AJ, Geba GP, ADVANTAGE Study Group (2003) Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. *Ann Intern Med* 139:539–546
29. Grant B (2009) Merck published fake journal. *The Scientist* <http://www.the-scientist.com/blog/display/55671>. Accessed 23 June 2009
30. U.S. Food and Drug Administration (1998) Warning letter from FDA's division of drug marketing and communications to Merck regarding aggrastat. <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLettersToPharmaceuticalCompanies/UCM167857.pdf>. Accessed 07 January 2010
31. Ratner M (2009) Pfizer settles largest ever fraud suit for off-label promotion. *Nat Biotechnol* 27:961–962
32. Tesorieri H (2008) Federal grand jury probes Merck's handling of Vioxx. *Wall Street Journal*. <http://online.wsj.com/article/SB120182583816633697.html>. Accessed 07 January 2010
33. Singh G, Miller JD, Huse DM, Pettitt D, D'Agostino RB, Russell MW (2003) Consequences of increased systolic blood pressure in patients with osteoarthritis and rheumatoid arthritis. *J Rheumatol* 30:714–719
34. Götzsche PC (1989) Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal, antiinflammatory drugs in rheumatoid arthritis. *Controlled Clin Trials* 10:31–56
35. Bero LA, Rennie D (1996) Influences on the quality of published drug studies. *Int J Tech Assess Health Care* 12:209–237
36. Safer DJ (2002) Design and reporting modifications in industry-sponsored comparative psychopharmacology trials. *J Nerv Ment Dis* 190:583–592
37. Melander H, Ahlqvist-Rastad J, Meijer G, Beerermann B (2003) Evidence b(i)ased medicine -selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. *BMJ* 326:1171–1173
38. Bero L, Oostvogel F, Bacchetti P, Lee K (2007) Factors associated with findings of published trials of drug–drug comparisons: why some statins appear more efficacious than others. *PLoS Med* 4:e184
39. Hrachovec JB (2001) Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. *JAMA* 286:2398
40. Jüni P, Rutjes AW, Dieppe PA (2002) Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? *BMJ* 324:1287–1288
41. Brophy JM (2005) Selling safety—lessons from muraglitazar. *JAMA* 294:2633–2635
42. Nissen SE, Wolski K, Topol EJ (2005) Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. *JAMA* 294:2581–2586
43. Vedula SS, Bero L, Scherer RW, Dickersin K (2009) Outcome reporting in industry-sponsored trials of gabapentin for off-label use. *N Engl J Med* 361:1963–1971
44. Grill M (2007) *Kranke Geschäfte: wie die Pharmaindustrie uns manipuliert*. Rowohlt Verlag, Hamburg
45. Mundy A (2001) *Dispensing with the truth*. St. Martin's Press, New York
46. Angell M (2004) *The truth about the drug companies: how they deceive us and what to do about it*. Random House, New York
47. Petersen M (2008) *Our daily meds*. Sarah Crichton, New York
48. Schafer A (2004) *Biomedical conflicts of interest: a defence of the sequestration thesis—learning from the cases of Nancy Olivieri and David Healy*. *J Med Ethics* 30:8–24
49. Revill J (2005) Doctor accuses drug giant of 'unethical' secrecy. *Observer*. <http://www.guardian.co.uk/uk/2005/dec/04/health.healthandwellbeing>. Accessed 23 June 2009
50. Revill J (2005) How the drugs giant and a lone academic went to war. *Observer*. <http://www.guardian.co.uk/uk/2005/dec/04/health.businessofresearch>. Accessed 23 June 2009
51. Bosely S (2004) Junket time in Munich for the medical profession—and it's all on the drug firms. *Guardian*. <http://www.guardian.co.uk/uk/2004/oct/05/highereducation.businessofresearch>. Accessed 23 June 2009
52. Tanne JH (2007) FDA places “black box” warning on antidiabetes drugs. *BMJ* 334:1237
53. Mello MM, Clarridge BR, Studdert DM (2005) Academic medical centers' standards for clinical-trial agreements with industry. *N Engl J Med* 352:2202–2210
54. Shuchman M (1999) Drug company threatens legal action over Canadian guidelines. *BMJ* 319:1388
55. Williams HC (2003) Evening primrose oil for atopic dermatitis. *BMJ* 327:1358–1259
56. Gornall J (2009) Industry attack on academics. *BMJ* 338:b736
57. Braitwaite J (1984) *Corporate crime in the pharmaceutical industry*. Routledge & Kegan Paul, London
58. Avorn J (2005) *Powerful medicines: the benefits, risks, and costs of prescription drugs*. Vintage, New York
59. Gozner M (2005) *The \$800 million pill: the truth behind the cost of new drugs*. University of California Press, Berkeley
60. CBS News (2007) OxyContin's deception costs firm \$634 M. <http://www.cbsnews.com/stories/2007/05/10/health/main2785453.shtml>. Accessed 23 June 2009
61. Graham DJ (2006) COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense. *JAMA* 296:1653–1656
62. Avorn J (2006) Dangerous deception—hiding the evidence of adverse drug effects. *N Engl J Med* 355:2169–2171
63. Steinman MA, Harper GM, Chren MM, Landefeld CS, Bero LA (2007) Characteristics and impact of drug detailing for gabapentin. *PLoS Med* 4:e134
64. Ziegler MG, Lew P, Singer BC (1995) The accuracy of drug information from pharmaceutical sales representatives. *JAMA* 273:1296–1298
65. Perry T (2008) Neurontin: clinical pharmacologic opinion of Dr. Thomas L. Perry. <http://dida.library.ucsf.edu/pdf/oxx18p10>. Accessed 23 June 2009
66. Topol EJ (2004) Failing the public health—rofecoxib, Merck, and the FDA. *N Engl J Med* 351:1707–1709
67. Graham DJ, Campen D, Hui R, Spence M, Cheatham C, Levy G, Shoor S, Ray WA (2005) Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. *Lancet* 365:475–481